Loefflers syndrome differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 16: Line 16:
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
|-
|-
| colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
| colspan="2" rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
! colspan="2" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
! colspan="2" rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
|-
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology
|-  
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased Eosinophil  
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased Eosinophil  
count  
count  
Line 40: Line 36:
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Transpulmonary
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Transpulmonary
passage of larvae (Loffler's syndrome)
passage of larvae (Loffler's syndrome)
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
* Cough
* Cough
* Sputum production
* Sputum production
*
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
* Wheezing
* Wheezing
* Fever
* Fever
| style="background: #F5F5F5; padding: 5px;" |
* Crackles
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 71: Line 67:


eosinophilia
eosinophilia
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
* Cough
* Cough
* Breathlessness
* Breathlessness
* Wheezing
* Fatigue
* Fatigue
*
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
* Fever.
* Fever.
| style="background: #F5F5F5; padding: 5px;" |
* Wheezing
| style="background: #F5F5F5; padding: 5px;" |
* Crackles
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* 40 to 70 percent (>3000/microL) plus elevated IgE  levels ( >1000 units/mL)
* 40 to 70 percent (>3000/microL) plus elevated IgE  levels ( >1000 units/mL)
Line 99: Line 95:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Allergic bronchopulmonary aspergillosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Allergic bronchopulmonary aspergillosis
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
* '''Repeated episodes of:'''
* '''Repeated episodes of:'''
* Bronchial obstruction, inflammation
* Bronchial obstruction, inflammation
Line 115: Line 111:
* Hemoptysis
* Hemoptysis
* Wheezing
* Wheezing
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Fever
| style="background: #F5F5F5; padding: 5px;" |
* Crackles
* Wheezing
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 139: Line 136:


helminths
helminths
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
* Depends on the organism for example:
* Depends on the organism for example:
* Periorbital edema, myositis, and eosinophilia ('''Trichinellosis)'''
* Periorbital edema, myositis, and eosinophilia ('''Trichinellosis)'''
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Depends on the organism for example:
| style="background: #F5F5F5; padding: 5px;" |
* Periorbital edema
* Tenderness in muscles
* Fever
* ('''Trichinellosis)'''
| style="background: #F5F5F5; padding: 5px;" |Mild to
| style="background: #F5F5F5; padding: 5px;" |Mild to
moderate to
moderate to
Line 167: Line 167:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary parenchymal invasion
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary parenchymal invasion
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Eosinophilia is  prominent in the early stages of disease but minimal with established disease
* Eosinophilia is  prominent in the early stages of disease but minimal with established disease
Line 188: Line 186:
| rowspan="2" |Nonhelminthic infections
| rowspan="2" |Nonhelminthic infections
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |
| colspan="2" rowspan="2" style="background: #F5F5F5; padding: 5px;" |
* Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure
* Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" rowspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 203: Line 199:
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Mycobacterium tuberculosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Mycobacterium tuberculosis
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 215: Line 208:
|-
|-
| colspan="2" |Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
| colspan="2" |Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
* Sinusitis
* Sinusitis
* Asthma,  
* Asthma,  
* Skin, cardiovascular, gastrointestinal, renal, and neurologic systems may also be involved.  
* Skin, cardiovascular, gastrointestinal, renal, and neurologic systems may also be involved.  
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* <small>1500 cells/microL</small>  
* <small>1500 cells/microL</small>  
Line 243: Line 234:
|-
|-
| colspan="2" |Drug- and toxin-induced eosinophilic lung diseases
| colspan="2" |Drug- and toxin-induced eosinophilic lung diseases
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
* Asymptomatic pulmonary infiltration with eosinophils
* Asymptomatic pulmonary infiltration with eosinophils
* Chronic cough with or without dyspnea, fever, acute eosinophilic pneumonia, and
* Chronic cough with or without dyspnea, fever, acute eosinophilic pneumonia, and
Line 251: Line 242:
* Enlarged lymph nodes
* Enlarged lymph nodes
* History of initiation of a culprit medication two to six weeks prior to disease onset
* History of initiation of a culprit medication two to six weeks prior to disease onset
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 271: Line 260:
|
|
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Chronic eosinophilic pneumonia
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Chronic eosinophilic pneumonia
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
* Predominantly in women and nonsmokers
* Predominantly in women and nonsmokers


* Following radiation therapy for breast cancer  
* Following radiation therapy for breast cancer  
* Cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats; asthma accompanies or precedes the illness in 50 percent of cases
* Cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats; asthma accompanies or precedes the illness in 50 percent of cases
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* ≥40 percent
* ≥40 percent
Line 301: Line 288:
|
|
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic acute eosinophilic pneumonia
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic acute eosinophilic pneumonia
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
* Acute respiratory failure in a previously healthy patient
* Acute respiratory failure in a previously healthy patient
*  
*  
Line 307: Line 294:
* Nonproductive cough
* Nonproductive cough
* Dyspnea,
* Dyspnea,
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* ≥25 percent
* ≥25 percent
Line 345: Line 330:
|
|
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sarcoidosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sarcoidosis
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 359: Line 342:
|
|
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary Langerhans cell histiocytosis (Histiocytosis X)
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary Langerhans cell histiocytosis (Histiocytosis X)
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 373: Line 354:
|
|
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic pulmonary fibrosis
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic pulmonary fibrosis
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |<10 percent
| style="background: #F5F5F5; padding: 5px;" |<10 percent
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 387: Line 366:
|
|
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 7
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 7
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| colspan="2" style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |

Revision as of 14:59, 11 June 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

Loeffler syndrome must be differentiated from other diseases that cause pulmonary eosinophilia, such as Churg-Strauss, drug and toxin-induced eosinophilic lung diseases, other helminthic and fungal infection related eosinophilic lung diseases, and nonhelminthic infections such as Coccidioidomycosis, and Mycobacterium tuberculosis.

Differentiating Loeffler syndrome from other pulmonary eosinophilia syndromes on the basis of etiology.

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Symptoms Physical examination
Lab Findings Imaging Histopathology
Increased Eosinophil

count

Other lab findings CXR CT Scan
Helminthic

and fungal infection-related

eosinophilic lung diseases

Transpulmonary

passage of larvae (Loffler's syndrome)

  • Cough
  • Sputum production
  • Wheezing
  • Fever
  • Crackles
  • Round or oval opacities (several millimeters to several centimeters)
  • In both lungs
  • Generally present when blood eosinophilia exceeds 10%
  • Migratory
  • May become confluent in perihilar areas
  • Generally clear spontaneously
  • Ascaris lumbricoides
  • Hookworms such as:
  • Ancylostoma duodenale
  • Necator americanus)
  • Strongyloides stercoralis
Tropical

pulmonary

eosinophilia

  • Cough
  • Breathlessness
  • Fatigue
  • Fever.
  • Wheezing
  • Crackles
  • 40 to 70 percent (>3000/microL) plus elevated IgE levels ( >1000 units/mL)
  • Diffuse opacities
  • Around 20% of patients have a normal CXR
  • Reticular and small nodular opacities
  • Bronchiectasis
  • Air trapping
  • Calcification
  • Mediastinal adenopathy
  • Wuchereria bancrofti
  • Brugia malayi
Allergic bronchopulmonary aspergillosis
  • Repeated episodes of:
  • Bronchial obstruction, inflammation
  • Mucoid impaction
  • Can lead to:
  • Bronchiectasis
  • Fibrosis
  • Respiratory compromise
  • Clinical picture of ABPA is dominated by underlying asthma (or cystic fibrosis)
  • Bronchial obstruction
  • Fever
  • Malaise,
  • Expectoration of brownish mucous plugs
  • Peripheral blood eosinophilia
  • Hemoptysis
  • Wheezing
  • Fever
  • Crackles
  • Wheezing
Mild to moderate
  • HRCT:
  • Widespread proximal cylindrical bronchiectasis with upper lobe predominance and bronchial wall thickening.
  • Central bronchiectasis with normal tapering of distal bronchi (classic manifestation of ABPA, neither sensitive nor specific)
  • Asthmatic bronchiolitis, eosinophilic pneumonia, bronchocentric granulomatosis, and mucoid impaction of bronchi
  • +/- bronchocentric granulomatosis (pulmonary eosinophilia in the absence of endobronchial fungi)
Heavy

hematogenous

seeding

with

helminths

  • Depends on the organism for example:
  • Periorbital edema, myositis, and eosinophilia (Trichinellosis)
  • Depends on the organism for example:
  • Periorbital edema
  • Tenderness in muscles
  • Fever
  • (Trichinellosis)
Mild to

moderate to

high

  • Trichinellosis: Ab will be positive 2-8 weeks after infection
  • Strongyloides: ELISA is generally positive while stool examination is often negative.
  • Strongyloides: diffuse ground glass opacities
  • Ascarids and hookworms
  • Trichinellosis
  • Disseminated strongyloidiasis
  • Cutaneous and visceral larva migrans
  • Schistosomiasis
  • Prior treatment with glucocorticoids may be a risk factor.
Pulmonary parenchymal invasion
  • Eosinophilia is prominent in the early stages of disease but minimal with established disease
  • Ab testing Useful in later infection with Paragonimus
  • Nodular with surrounding areas of ground glass
  • Peripheral
  • Common in the mid- and lower lung zones
  • Finding eggs in the sputum or bronchoalveolar lavage fluid
  • Helminths such as paragonimiasis
Nonhelminthic infections Coccidioidomycosis
  • Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure
  • Antibody testing may be negative early in the course of disease
Mycobacterium tuberculosis
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)
  • Sinusitis
  • Asthma,
  • Skin, cardiovascular, gastrointestinal, renal, and neurologic systems may also be involved.
  • 1500 cells/microL
  • > 10 percent of the total leukocyte count
  • Antineutrophil cytoplasmic antibodies (ANCA)
  • Myeloperoxidase (MPO) perinuclear staining pattern
  • Antineutrophil cytoplasmic antibodies (ANCA)
  • Myeloperoxidase (MPO) perinuclear staining pattern
  • Transient and patchy opacities without lobar or segmental distribution
  • lung biopsy:
  • Eosinophilic infiltrates
  • eosinophilic vasculitis (especially of the small arteries and veins)
  • Interstitial and perivascular necrotizing granulomas
  • Areas of necrosis
Drug- and toxin-induced eosinophilic lung diseases
  • Asymptomatic pulmonary infiltration with eosinophils
  • Chronic cough with or without dyspnea, fever, acute eosinophilic pneumonia, and
  • DRESS:
  • Skin eruption
  • Fever, Facial edema
  • Enlarged lymph nodes
  • History of initiation of a culprit medication two to six weeks prior to disease onset
Mild to moderate
  • Medications such as:
  • Nonsteroidal antiinflammatory drugs
  • Phenytoin
  • L-tryptophan
  • Antibiotics (nitrofurantoin, minocycline, sulfonamides, ampicillin, daptomycin)
  • Toxins such as:
  • Aluminum silicate and particulate metals •Sulfite •Scorpion stings •Inhalation of o heroin, crack cocaine, or marijuana •Inhalation of organic chemicals, dust or smoke, during rubber manufacture, fireworks, firefighting, tobacco smoking •Abuse of 1,1,1-trichloroethane (Scotchgard)
Chronic eosinophilic pneumonia
  • Predominantly in women and nonsmokers
  • Following radiation therapy for breast cancer
  • Cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats; asthma accompanies or precedes the illness in 50 percent of cases
  • ≥40 percent
  • Eosinophilia may be absent in 10-20% of patients
  • Bilateral peripheral or pleural-based infiltrates described as the "photographic negative" of pulmonary edema is virtually pathognomonic for the disease (in 33% of cases)
  • Pleural effusion
  • Cavitation
  • BAL eosinophilia ≥25 percent is suggestive of CEP.
  • Nodular bronchial mucosal lesions
  • Necrotizing eosinophilic inflammation
  • Lung biopsy:
  • Interstitial and alveolar eosinophils and histiocytes, including multinucleated giant cells
  • Fibrosis (minimal)
  • Organizing pneumonia (common)
Idiopathic acute eosinophilic pneumonia
  • Acute respiratory failure in a previously healthy patient
  • Acute febrile illness of less than seven days' duration, characterized by:
  • Nonproductive cough
  • Dyspnea,
  • ≥25 percent
  • Non specific but might reveal
  • Diffuse pulmonary opacities on imaging
  • Bronchoalveolar lavage that reveals ≥25 percent eosinophils
  • When the diagnosis is uncertain lung biopsy is recommended:
  • Histopathologic findings include:
  • Diffuse alveolar damage
  • Hyaline membranes
  • Marked numbers of interstitial and lesser numbers of alveolar eosinophils
  • Often associated with recent initiation or resumption of cigarette smoking
  • Less commonly with heavy inhalational exposure to smoke, fine sand, or dust
Diseases Symptom 1 Symptom 2 Physical exam 1 Physical exam 2 Increased Eosinophil count

(High)

Other lab findings CXR CT Scan Histopathology Gold standard Additional findings
Sarcoidosis Mild to moderate
Pulmonary Langerhans cell histiocytosis (Histiocytosis X) Mild to moderate
Idiopathic pulmonary fibrosis <10 percent
Differential Diagnosis 7

References

Template:WH Template:WS